SKU: Tesa5

Product Overview Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), consisting of 44 amino acids with a modified N-terminal trans-3-hexenoyl group for enhanced stability. This research peptide is designed to stimulate the pituitary gland, promoting the endogenous release of growth hormone (GH) and subsequent elevation of insulin-like growth factor-1 (IGF-1) levels. Available in a 5mg lyophilized vial, it is ideal for in vitro and in vivo studies exploring metabolic regulation, body composition, and hormonal pathways.

Key Research Applications

• Metabolic and Lipolytic Studies: Investigated for its potential to induce lipolysis and reduce triglyceride levels, particularly in models of visceral adipose tissue accumulation.
• Hormonal and Endocrine Research: Examines GH/IGF-1 axis modulation, including effects on somatotroph cell growth and gene transcription.
• Aging and Longevity Models: Explored for impacts on biomarkers such as adiponectin, inflammatory cytokines (e.g., IL-6, CRP), and epigenetic aging clocks.
• Neurological and Cognitive Investigations: Preliminary studies suggest neuroprotective effects, including improvements in verbal memory and executive function in cognitive impairment models.
• Other Emerging Areas: Nonalcoholic fatty liver disease (NAFLD), metabolic syndrome, and sarcopenia in preclinical settings.

Mechanism of Action (Research Context) Tesamorelin binds to GHRH receptors on pituitary somatotroph cells, activating adenylyl cyclase via G-protein coupling. This triggers intracellular cAMP accumulation, leading to GH secretion and downstream anabolic/lipolytic effects. In experimental models, it demonstrates prolonged GH elevation (up to 8 hours post-administration) compared to native GHRH, due to resistance against enzymatic degradation by dipeptidyl peptidase-4 (DPP-4).